NEW YORK, NY / ACCESSWIRE / July 6, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
First High-School Education Group Co., Ltd. (NYSE:FHS)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/first-high-school-education-group-co-ltd-loss-submission-form?prid=29592&wire=1
Lead Plaintiff Deadline: July 11, 2022
This lawsuit is on behalf of all persons or entities who purchased FHS American Depositary Shares in or traceable to the Company's March 2021 initial public offering.
Allegations against FHS include that: (a) the new rules, regulations and policies to be implemented by the Chinese government following the Two Sessions parliamentary meetings were far more severe than represented to investors and posed a material adverse threat to the Company and its business; (b) contemplated Chinese regulations and rules regarding private education were leading to a slowdown of government approval to open new educational facilities which would have a negative effect on FHS's enrollment and growth; and (c) as a result, representations made in connection with the Company's initial public offering regarding FHS's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company at the time of the initial public offering, and were materially false and misleading and lacked a factual basis.
Spero Therapeutics, Inc. (NASDAQ:SPRO)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=29592&wire=1
Lead Plaintiff Deadline: July 25, 2022
Class Period: October 28, 2021 - May 2, 2022
Allegations against SPRO include that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
IonQ, Inc. (NYSE:IONQ)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ionq-inc-loss-submission-form?prid=29592&wire=1
Lead Plaintiff Deadline: August 1, 2022
Class Period: March 30, 2021 - May 2, 2022
Allegations against IONQ include that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) the Company's 11-qubit quantum computer suffered from significant error rates, rendering it useless; (3) IonQ's quantum the computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers; (4) a significant portion of IonQ's revenue was derived from improper roundtripping transactions with related parties; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were the materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong